Soumit Roy
Stock Analyst at Edward Jones
(3.36)
# 1,027
Out of 5,090 analysts
42
Total ratings
30.3%
Success rate
11.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVAX Evaxion | Initiates: Buy | $10 | $5.25 | +90.48% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $4.40 | - | 1 | Oct 24, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $43.30 | +15.47% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $5.58 | +276.34% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $24.69 | +62.01% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $21.81 | +23.80% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $2.37 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $0.99 | - | 2 | May 16, 2025 | |
| CRVO CervoMed | Upgrades: Buy | $15 | $8.69 | +72.61% | 3 | Mar 13, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $10 | $8.55 | +16.96% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $27.09 | +25.51% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $1.79 | +1,911.17% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $3.06 | +945.75% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.00 | +12.50% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $11.00 | +54.55% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.42 | +437.19% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.53 | +648.78% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.19 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.42 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $10.59 | +145.51% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $16.51 | +323.99% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $80.38 | -87.56% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.46 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $15.70 | +409.55% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.50 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $1.98 | +16,061.62% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $5.02 | +16,035.46% | 1 | Feb 24, 2021 |
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.25
Upside: +90.48%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $4.40
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $43.30
Upside: +15.47%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $5.58
Upside: +276.34%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $24.69
Upside: +62.01%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $21.81
Upside: +23.80%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.37
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.99
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $8.69
Upside: +72.61%
Nuvation Bio
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $8.55
Upside: +16.96%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $27.09
Upside: +25.51%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $1.79
Upside: +1,911.17%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $3.06
Upside: +945.75%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $8.00
Upside: +12.50%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $11.00
Upside: +54.55%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $2.42
Upside: +437.19%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.53
Upside: +648.78%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.19
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.42
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $10.59
Upside: +145.51%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $16.51
Upside: +323.99%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $80.38
Upside: -87.56%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $5.46
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $15.70
Upside: +409.55%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.50
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $1.98
Upside: +16,061.62%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $5.02
Upside: +16,035.46%